van de Beek, M.
Babapour Mofrad, R.
van Steenoven, I.
Vanderstichele, H.
Scheltens, P.
Teunissen, C. E.
Lemstra, A. W.
van der Flier, W. M.
Article History
Received: 15 October 2019
Accepted: 31 March 2020
First Online: 17 April 2020
Ethics approval and consent to participate
: Written informed consent was obtained from all study participants for the use of clinical data and biomaterial for research purposes. This study was approved by the local medical ethical committee of the Amsterdam UMC, location VUmc.
: Not applicable.
: Prof. Dr. Teunissen has a collaboration contract with ADx Neurosciences and performed contract research or received grants from Probiodrug, AC Immune, Biogen-Esai, CogRx, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche. Prof. Dr. Scheltens has acquired grant support (for the institution) from GE Healthcare and Piramal. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Novartis, Probiodrug, Biogen, Roche, and EIP Pharma, LLC. Dr. Lemstra has received funding from stichting Dioraphte and ZonMW Memorabel (project #733050509). Research programs of Prof. Dr. Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Biogen MA Inc., Life-MI, AVID, and Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc. All funding is paid to her institution. Van de Beek, Babapour Mofrad, van Steenoven, Dr. vanderStichele report no disclosures relevant to this manuscript.